Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-04-27 Annual Report
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
2020 Annual Report
Annual Report Classification · 100% confidence The document is titled '2020 Annual Report ALPHAMAB ONCOLOGY' and contains extensive sections typical of an annual report, including company profile, corporate information, chairman's statement, management discussion and analysis, profiles of directors and senior management, corporate governance report, directors' report, independent auditor's report, consolidated financial statements, and notes to the financial statements. The length of the document (15,000 characters) and the detailed financial and operational information confirm it is a full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-04-27 English
GRANT OF SHARE OPTIONS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the grant of share options to employees and directors of Alphamab Oncology. It details the number of options granted, exercise price, vesting period, and compliance with listing rules. There is no financial report, earnings data, or management discussion. The content focuses on share option grants, which is a capital-related update. The document is relatively short (3896 characters) and is a formal announcement of a share option grant, fitting the category of Capital/Financing Update (CAP).
2021-04-23 English
VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the release of preliminary safety, tolerability, and efficacy results of a clinical study (KN046-203) presented as an e-poster at the 2021 AACR Annual Meeting. It provides detailed clinical trial data, including patient enrollment, endpoints, and outcomes, but it is not a full financial report or regulatory filing. The document is an announcement of clinical trial results and business progress rather than a formal financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation or transcript of a call. Given the nature of the content—an announcement of clinical trial results and business update—the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories. The document length (8656 characters) and detailed content confirm it is not a brief report publication announcement or a short notice. Confidence is high due to clear content type and context.
2021-04-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/03/2021 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements to the exchange, consistent with regulatory compliance disclosures rather than a financial report or announcement of voting results. The document length is substantial (15,000 characters), and it contains detailed data rather than a brief announcement or certification. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement about share capital movements that does not fit into more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS), since no new shares were issued or repurchased during the month (all increases/decreases are nil).
2021-04-09 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER
Board/Management Information Classification · 100% confidence The document is a voluntary announcement by Alphamab Oncology regarding the appointment of a Chief Medical Officer and a Chief Financial Officer. It contains biographical details of the appointees and the effective dates of their appointments. There is no financial data, no mention of a report or filing, and the document is relatively short (3863 characters). This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-03-30 English
ADOPTION OF THE RESTRICTED SHARE AWARD SCHEME
Capital/Financing Update Classification · 95% confidence The document is an announcement by Alphamab Oncology regarding the adoption of a Restricted Share Award Scheme. It details the scheme's objectives, administration, operation, vesting conditions, restrictions, and amendment provisions. The content focuses on the company's equity incentive plan and does not contain financial statements, earnings data, or regulatory certifications. It is not a report of financial results, management discussion, or regulatory filing but an announcement of a new share award scheme. This fits the category of a Capital/Financing Update (CAP) as it relates to the company's capital structure and equity incentive arrangements.
2021-03-23 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.